IP Library Granted Patent US 10,357,567
Granted Patent B1
US 10,357,567 · App. 15/869,164 · Granted Jul 23, 2019

Methods for photodynamic therapy

Inventors: Scott Lundahl (Lexington, MA); Michael Guttadauro (Carlisle, MA)
Assignee: DUSA Pharmaceuticals, Inc.
A61K41/0061A61K9/0014A61K31/75A61N5/062A61P17/12A61N2005/0652A61N2005/0659A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,357,567
App. No.
15/869,164
Granted
Jul 23, 2019
Kind
B1
Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

Claims (21)

1. A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy, the method comprising:

topically applying ALA to a treatment area to be treated with photodynamic therapy;

after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area; and

removing the low density polyethylene barrier within 3 hours and then applying light to the treatment area.

2. A method as set forth in claim 1 , wherein the low density polyethylene barrier is removed from the treatment area within 3 hours and then blue light is applied to the treatment area for a 10 J/cm 2 light dose.

3. The method of claim 1 , wherein a maximum plasma concentration of ALA following application of the ALA is less than about 110 ng/mL.

4. A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy, the method comprising:

topically applying ALA to a treatment area to be treated with photodynamic therapy; and

after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area,

wherein the treatment area is located on a hand or a forearm.

5. A method as set forth in claim 4 , wherein the low density polyethylene barrier is removed from the treatment area and then red light is applied to the treatment area for a 10 to 75 J/cm 2 light dose.

6. The method as set forth in claim 4 , wherein the treatment area is a dorsal surface of the hand.

7. The method as set forth in claim 4 , wherein the treatment area is a dorsal surface of the forearm.

8. A method of using 5-aminolevulinic acid (ALA) and a low density polyethylene barrier, comprising:

contacting a treatment site with a composition comprising the ALA so as to wet the treatment site;

following wetting of the treatment site, covering the wetted treatment site with the low density polyethylene barrier;

removing the low density polyethylene barrier so as to expose the treatment site; and

illuminating the exposed treatment site with an illuminator so as to deliver a 10 J/cm 2 dose of blue light.

9. The method of claim 8 , wherein the low density polyethylene barrier is removed no later than three hours after the treatment site is covered.

10. The method of claim 8 , further comprising:

positioning the treatment site between two inches and four inches from a surface of the illuminator.

Assignments (2)
MERGER Recorded May 30, 2024
From: DUSA PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 067565/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2018
From: LUNDAHL, SCOTT; GUTTADAURO, MICHAEL
To: DUSA PHARMACEUTICALS, INC.
Reel/Frame 045074/0219 →
Cited By (5)
US 1,067,446 US 1,077,259 US 1,143,047 US 12,290,700 US 12,296,011